ArticleAnnals of surgical oncology2026
Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation for Esophageal Adenocarcinoma: A National Cancer Database Analysis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile neoadjuvant chemoradiation (NCRT) has been the acceptable standard of care for esophageal adenocarcinoma (EAC), there has been a paradigm shift based on recent trials showing neoadjuvant chemotherapy (NCT) as being either equivalent or superior to NCRT. We sought to examine the outcomes of NCT versus NCRT in esophageal cancer.
methodsUtilizing the National Cancer Database, we identified esophagectomy patients with EAC who underwent multi-agent NCT versus multi-agent NCRT. Groups were statistically equated with propensity score-matched (PSM) analysis.
resultsAfter PSM, we identified 1007 patients in each group. There was improved lymphadenectomy and higher use of adjuvant therapy in the NCT group, and significant improvements in R0 resection and pathologic response associated with NCRT. There was also a significant improvement in overall survival (OS) in the NCT versus NCRT groups. The median and 5-year OS were 42.7 months and 42% in NCT versus 34.2 months and 35% in NCRT (p = 0.001). For pathologic complete responders, median and 5-year OS were 101 months and 64% in NCT versus 71.2 months and 53% in NCRT (p = 0.04). On multivariate analysis, reduced mortality was associated with female sex, pathologic N0, >10 nodes removed, pathologic partial or complete response, R0, well/moderate grade, NCT, adjuvant chemotherapy, and higher facility volume.
conclusionsDespite the higher R0 rate and pathologic response associated with NCRT, NCT was associated with improved OS compared with NCRT in EAC patients. While NCT shows an OS advantage in this dataset, regimen heterogeneity precludes definitive therapeutic recommendations.
Indexed as
Identifiers
40849389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.